阿立哌唑联合奥氮平治疗精神分裂症的临床疗效分析

Clinical Efficacy Analysis of Aripiprazole Combined with Olanzapine in the Treatment of Schizophrenia

目的:分析阿立哌唑联合奥氮平治疗精神分裂症的临床疗效。方法:选取2019年4月-2022年4月淮安市新安医院收治的精神分裂症患者30例为研究对象,根据随机数字表法分为对照组和观察组,各15例。对照组给予奥氮平治疗,观察组给予阿立哌唑联合奥氮平治疗,比较两组患者糖代谢指标、体重相关指标、临床症状评分、治疗效果、不良反应发生率。结果:治疗后,两组患者空腹血糖(FPG)、餐后2h血糖(2hPG)、总胆固醇(TC)、三酰甘油(TG)及高密度脂蛋白-胆固醇(LDL-C)水平均升高,低密度脂蛋白-胆固醇(HDL-C)水平均降低,但观察组FPG、2hPG、TC、TG、LDL-C水平低于对照组,HDL-C水平高于对照组,差异有统计学意义(P<0.05);治疗后,两组患者体重、体重指数水平均升高,但观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组患者阳性症状、阴性症状、精神病理评分及总分均降低,观察组低于对照组,差异有统计学意义(P<0.05);观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论:阿立哌唑联合奥氮平治疗精神分裂症可改善患者糖脂代谢水平,缓解临床症状,临床疗效显著,安全性较高。

Objective:To analyze the clinical efficacy of aripiprazole combined with olanzapine in the treatment of schizophrenia.Methods:Thirty patients with schizophrenia admited to Huai'an Xin'an Hospital from April 2019 to April 2022 were selected as studysubjects and divided into control group and observation group according to the random number table method,with 15 cases each.Thecontrol group was given olanzapine treatment and he observation group was given aripiprazole combined with olanzapine treatment,and the glucose metabolism index,weight-related index,clinical symptom score,treatment ffect,and incidence of adverse reactionswere compared between the two groups.Resuls:After treatment,fasting glucose(FPG),2h postprandial glucose(2hPG),total cholesterol(TC),triacylglycerol(TC)and high-density lipoprotein-cholesterol(LDL-C)levels increased and low-densitylipoprotein-cholesterol(HDL-C)levels decreased in both groups,but FPG,2hPG,TC,TG and LDL-C levels in the observation groupwere lower than those in the control group,and HDL-C levels were higher than those in the control group.HDL-C levels were higherthan those of the contrl group,and the dfference was statisticaly significant(P<0.05)fter treatment,the weight and body massindex levels increased in both groups,but the observation group was lower than the control group,and the dfference was statisticallysignificant(P<0.05).Afer treatment,the positive symptoms,negative symptoms,psychopathology scores and total scores of atients inboth groups were reduced,and the observation group was lower than the control group,and the difference was statistically significant(P<0.05).The total treatment efficiency of the observation group was higher than that of the control group,and the difference wasstatistically significant(P<0.05).The incidence of adverse reactions in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion:Aripiprazole combined with olanzapine for schizophrenia canimprove patients'glucose and lipid metabolism levels and relieve clinical symptoms,with significant clinical eficacy and high safety.